Incumbent U.S. Representative Tom Malinowski (D-NJ-07) appears to have financially benefited from exceptional timing during the COVID-19 pandemic.
The Hill reported in 2021 that Malinowski previously faced two ethics complaints about his failure to report “trading roughly $1 million in stock in medical companies that were involved in responses to the COVID-19 pandemic.”
Malinowski’s stock trades, when viewed in the context of the COVID-19 timeline in the United States, lead reporters at The Hill and The AP to more closely follow his financial activities. However, The Star News Network, using publicly available and verified information, found that Malinowski benefitted from an extraordinary navigation of technology, luxury, and medical market sectors.
Read the full story